Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor Appendix Abbreviations Other Indication NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Indication NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase Phase 3 Phase Phase 3 Patients 489 Patients 268 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Primary Outcome Measures Measures Target Patients Readout Milestone(s) Publication TBD Arms Intervention Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Primary 2026 Arms Intervention Target Patients Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Arm 2: Placebo comparator Patients with active Sjogren's syndrome Readout Primary 2026 Milestone(s) Publication TBD 71 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation